PhageBank™ Deployed in Texas Outbreak of Life-Threatening Carbapenem Resistant A. baumannii (CRAB) in COVID-19 Patients

  04 November 2020

Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced a deployment in Texas of its investigational PhageBank™ therapy in response to a deadly outbreak of secondary infections with carbapenem resistant Acinetobacter baumannii (CRAB) bacteria in COVID-19 patients. Mortality rates were more than two-fold higher in COVID-19 patients with secondary CRAB infection, versus 32% mortality in patients without secondary CRAB infections.

Further reading: BusinessWire
Author(s): BusinessWire
Healthy Patients  


Unrestricted financial support kindly provided by

Antimicrobial Resistance Fighter Coalition

Technology Database

Display your AMR Technology, Product and Service


Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.


Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!